These findings suggest that NRG1 promotes AR resistance through paracrine activation of PI3K-AKT signaling in PTEN wild-type prostate cancer and highlights a compelling rationale for combining AR-targeted therapy with NRG1-HER2/HER3 inhibition in selected patient populations [17,22]. The gene discussed is NRG1; the disease is prostate carcinoma.